{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:30:11Z","timestamp":1789885811717,"version":"4.0.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["0000"],"award-info":[{"award-number":["0000"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dementia Platform UK (DPUK) NIHR Imperial Biomedical Research Centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:sup>11<\/jats:sup>\n                    C-BU99008 is a novel positron emission tomography (PET) tracer that enables selective imaging of astrocyte reactivity in vivo. To explore astrocyte reactivity associated with Alzheimer\u2019s disease, 11 older, cognitively impaired (CI) subjects and 9 age-matched healthy controls (HC) underwent 3T magnetic resonance imaging (MRI),\n                    <jats:sup>18<\/jats:sup>\n                    F-florbetaben and\n                    <jats:sup>11<\/jats:sup>\n                    C-BU99008 PET. The 8 amyloid (A\u03b2)-positive CI subjects had higher\n                    <jats:sup>11<\/jats:sup>\n                    C-BU99008 uptake relative to HC across the whole brain, but particularly in frontal, temporal, medial temporal and occipital lobes. Biological parametric mapping demonstrated a positive voxel-wise neuroanatomical correlation between\n                    <jats:sup>11<\/jats:sup>\n                    C-BU99008 and\n                    <jats:sup>18<\/jats:sup>\n                    F-florbetaben. Autoradiography using\n                    <jats:sup>3<\/jats:sup>\n                    H-BU99008 with\n                    <jats:italic>post-mortem<\/jats:italic>\n                    Alzheimer\u2019s brains\u00a0confirmed through visual assessment that increased\n                    <jats:sup>3<\/jats:sup>\n                    H-BU99008 binding localised with the astrocyte protein glial fibrillary acid protein and was not displaced by PiB or florbetaben. This proof-of-concept study provides direct evidence that\n                    <jats:sup>11<\/jats:sup>\n                    C-BU99008 can measure in vivo astrocyte reactivity in people with late-life cognitive impairment and Alzheimer\u2019s disease. Our results confirm that increased astrocyte reactivity is found particularly in cortical regions with high A\u03b2 load. Future studies now can explore how clinical expression of disease varies with astrocyte reactivity.\n                  <\/jats:p>","DOI":"10.1038\/s41380-021-01193-z","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T01:02:36Z","timestamp":1626310956000},"page":"5848-5855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load"],"prefix":"10.1038","volume":"26","author":[{"given":"Valeria","family":"Calsolaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-8328","authenticated-orcid":false,"given":"Paul M.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius K.","family":"Donat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6582-2545","authenticated-orcid":false,"given":"Nicholas R.","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia D.","family":"Femminella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Silva","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin J.","family":"Tyacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin V.","family":"Venkataraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-6687","authenticated-orcid":false,"given":"Eugenii A.","family":"Rabiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Gentleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Wren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7808-9207","authenticated-orcid":false,"given":"Rainer","family":"Hinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-1401","authenticated-orcid":false,"given":"David J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6551-2002","authenticated-orcid":false,"given":"Paul","family":"Edison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"1193_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14:388\u2013405.","journal-title":"Lancet Neurol"},{"key":"1193_CR2","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1007\/s00415-017-8593-x","volume":"264","author":"Z Cai","year":"2017","unstructured":"Cai Z, Wan CQ, Liu Z. Astrocyte and Alzheimer\u2019s disease. J Neurol. 2017;264:2068\u201374.","journal-title":"J Neurol"},{"key":"1193_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P. Neuroinflammation in Alzheimer\u2019s disease: current evidence and future directions. Alzheimers Dement. 2016;12:719\u201332.","journal-title":"Alzheimers Dement"},{"key":"1193_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1096\/fj.12-208660","volume":"27","author":"AW Kraft","year":"2013","unstructured":"Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP\/PS1 mice. FASEB J. 2013;27:187\u201398.","journal-title":"FASEB J"},{"key":"1193_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/cns.12267","volume":"20","author":"M Xiao","year":"2014","unstructured":"Xiao M, Hu G. Involvement of aquaporin 4 in astrocyte function and neuropsychiatric disorders. CNS Neurosci Ther. 2014;20:385\u201390.","journal-title":"CNS Neurosci Ther"},{"key":"1193_CR6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2174\/1570159X15666170208124324","volume":"15","author":"P Muszynski","year":"2017","unstructured":"Muszynski P, Groblewska M, Kulczynska-Przybik A, Kulakowska A, Mroczko B. YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer\u2019s disease. Curr Neuropharmacol. 2017;15:906\u201317.","journal-title":"Curr Neuropharmacol"},{"key":"1193_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3233\/JAD-2009-1075","volume":"17","author":"S Jesse","year":"2009","unstructured":"Jesse S, Steinacker P, Cepek L, von Arnim CA, Tumani H, Lehnert S, et al. Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer\u2019s disease and Creutzfeldt-Jakob disease. J Alzheimers Dis. 2009;17:541\u201351.","journal-title":"J Alzheimers Dis"},{"key":"1193_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fnagi.2013.00061","volume":"5","author":"V Lam","year":"2013","unstructured":"Lam V, Albrecht MA, Takechi R, Giles C, James AP, Foster JK, et al. The serum concentration of the calcium binding protein S100B is positively associated with cognitive performance in older adults. Front Aging Neurosci. 2013;5:61.","journal-title":"Front Aging Neurosci"},{"key":"1193_CR9","doi-asserted-by":"crossref","unstructured":"Carter SF, Sch\u00f6ll M, Almkvist O, Wall A, Engler H, L\u00e5ngstr\u00f6m B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J. Nucl. Med. 2012;53:37\u201346.","DOI":"10.2967\/jnumed.110.087031"},{"key":"1193_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molmed.2018.11.006","volume":"25","author":"SF Carter","year":"2019","unstructured":"Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Astrocyte biomarkers in Alzheimer\u2019s disease. Trends Mol Med. 2019;25:77\u201395.","journal-title":"Trends Mol Med"},{"key":"1193_CR11","doi-asserted-by":"publisher","first-page":"153601211879231","DOI":"10.1177\/1536012118792317","volume":"17","author":"V Narayanaswami","year":"2018","unstructured":"Narayanaswami V, Dahl K, Bernard-Gauthier V, Josephson L, Cumming P, Vasdev N, et al. Radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: outlook beyond TSPO. Mol Imaging. 2018;17:1536012118792317.","journal-title":"Mol Imaging"},{"key":"1193_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00259-015-3047-0","volume":"42","author":"E Rodriguez-Vieitez","year":"2015","unstructured":"Rodriguez-Vieitez E, Ni R, Gulyas B, Toth M, Haggkvist J, Halldin C, et al. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. Eur J Nucl Med Mol Imaging. 2015;42:1119\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1193_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/jnr.490340611","volume":"34","author":"S Regunathan","year":"1993","unstructured":"Regunathan S, Feinstein DL, Reis DJ. Expression of non-adrenergic imidazoline sites in rat cerebral cortical astrocytes. J Neurosci Res. 1993;34:681\u20138.","journal-title":"J Neurosci Res"},{"key":"1193_CR14","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/j.1471-4159.1993.tb03599.x","volume":"61","author":"M Sastre","year":"1993","unstructured":"Sastre M, Garcia-Sevilla JA. Opposite age-dependent changes of alpha 2A-adrenoceptors and nonadrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) in the human brain: strong correlation of I2 with monoamine oxidase-B sites. J Neurochem. 1993;61:881\u20139.","journal-title":"J Neurochem"},{"key":"1193_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0304-3940(98)00265-1","volume":"247","author":"JA Garcia-Sevilla","year":"1998","unstructured":"Garcia-Sevilla JA, Escriba PV, Walzer C, Bouras C, Guimon J. Imidazoline receptor proteins in brains of patients with Alzheimer\u2019s disease. Neurosci Lett. 1998;247:95\u20138.","journal-title":"Neurosci Lett"},{"key":"1193_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00213-003-1392-3","volume":"167","author":"DP Finn","year":"2003","unstructured":"Finn DP, Marti O, Harbuz MS, Valles A, Belda X, Marquez C, et al. Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology. 2003;167:195\u2013202.","journal-title":"Psychopharmacology"},{"key":"1193_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1749-6632.1999.tb09344.x","volume":"881","author":"AL Hudson","year":"1999","unstructured":"Hudson AL, Gough R, Tyacke R, Lione L, Lalies M, Lewis J, et al. Novel selective compounds for the investigation of imidazoline receptors. Ann N Y Acad Sci. 1999;881:81\u201391.","journal-title":"Ann N Y Acad Sci"},{"key":"1193_CR18","first-page":"37","volume":"106","author":"AL Hudson","year":"1999","unstructured":"Hudson AL, Lione LA. Characterization of imidazoline receptors by radioligand binding. Methods Mol Biol. 1999;106:37\u201347.","journal-title":"Methods Mol Biol"},{"key":"1193_CR19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/syn.21541","volume":"66","author":"RJ Tyacke","year":"2012","unstructured":"Tyacke RJ, Fisher A, Robinson ES, Grundt P, Turner EM, Husbands SM, et al. Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1H-imidazol-2-yl)-1- methyl-1H-indole), for the imidazoline(2) binding site. Synapse. 2012;66:542\u201351.","journal-title":"Synapse"},{"key":"1193_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2967\/jnumed.112.108258","volume":"54","author":"S Kealey","year":"2013","unstructured":"Kealey S, Turner EM, Husbands SM, Salinas CA, Jakobsen S, Tyacke RJ, et al. Imaging imidazoline-I2 binding sites in porcine brain using 11C-BU99008. J Nucl Med. 2013;54:139\u201344.","journal-title":"J Nucl Med"},{"key":"1193_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2016.10.005","volume":"45","author":"K Kawamura","year":"2017","unstructured":"Kawamura K, Shimoda Y, Yui J, Zhang Y, Yamasaki T, Wakizaka H, et al. A useful PET probe [(11)C]BU99008 with ultra-high specific radioactivity for small animal PET imaging of I2-imidazoline receptors in the hypothalamus. Nucl Med Biol. 2017;45:1\u20137.","journal-title":"Nucl Med Biol"},{"key":"1193_CR22","doi-asserted-by":"publisher","first-page":"838","DOI":"10.2967\/jnumed.113.131854","volume":"55","author":"CA Parker","year":"2014","unstructured":"Parker CA, Nabulsi N, Holden D, Lin SF, Cass T, Labaree D, et al. Evaluation of 11C-BU99008, a PET ligand for the imidazoline2 binding sites in rhesus brain. J Nucl Med. 2014;55:838\u201344.","journal-title":"J Nucl Med"},{"key":"1193_CR23","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2967\/jnumed.118.208009","volume":"59","author":"RJ Tyacke","year":"2018","unstructured":"Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J, et al. Evaluation of (11)C-BU99008, a PET ligand for the imidazoline2 binding site in human brain. J Nucl Med. 2018;59:1597\u2013602.","journal-title":"J Nucl Med"},{"key":"1193_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0429-x","volume":"8","author":"AV Venkataraman","year":"2018","unstructured":"Venkataraman AV, Keat N, Myers JF, Turton S, Mick I, Gunn RN, et al. First evaluation of PET-based human biodistribution and radiation dosimetry of (11)C-BU99008, a tracer for imaging the imidazoline2 binding site. EJNMMI Res. 2018;8:71.","journal-title":"EJNMMI Res"},{"key":"1193_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"1193_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"1193_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.nicl.2017.04.025","volume":"15","author":"S Bullich","year":"2017","unstructured":"Bullich S, Seibyl J, Catafau AM, Jovalekic A, Koglin N, Barthel H, et al. Optimized classification of (18)F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. Neuroimage Clin. 2017;15:325\u201332.","journal-title":"Neuroimage Clin"},{"key":"1193_CR28","doi-asserted-by":"crossref","unstructured":"Tyacke RJ, Myers JFM, Venkataraman A, Mick I, Turton S, Passchier J, et al. Evaluation of (11)C-BU99008, a positron emission tomography ligand for the Imidazoline2 binding site in human brain. J Nucl Med. 2018.","DOI":"10.2967\/jnumed.118.208009"},{"key":"1193_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/jcbfm.1993.5","volume":"13","author":"VJ Cunningham","year":"1993","unstructured":"Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab. 1993;13:15\u201323.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1193_CR30","doi-asserted-by":"crossref","unstructured":"Veronese M, Rizzo G, Bertoldo A, Turkheimer FE. Spectral analysis of dynamic PET studies: a review of 20 years of method developments and applications. Comput Math Methods Med. 2016;2016:7187541.","DOI":"10.1155\/2016\/7187541"},{"key":"1193_CR31","doi-asserted-by":"crossref","unstructured":"Casanova R, Srikanth R, Baer A, Laurienti PJ, Burdette JH, Hayasaka S, et al. Biological parametric mapping: A statistical toolbox for multimodality brain image analysis. NeuroImage. 2007;34::137\u201343.","DOI":"10.1016\/j.neuroimage.2006.09.011"},{"key":"1193_CR32","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/j.1476-5381.2008.00107.x","volume":"156","author":"G Riedel","year":"2009","unstructured":"Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol. 2009;156:1154\u201366.","journal-title":"Br J Pharmacol"},{"key":"1193_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-12679-1_1","volume":"215","author":"H Braak","year":"2015","unstructured":"Braak H, Del, Trecidi K. Neuroanatomy and pathology of sporadic Alzheimer\u2019s disease. Adv Anat Embryol Cell Biol. 2015;215:1\u2013162.","journal-title":"Adv Anat Embryol Cell Biol"},{"key":"1193_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0304-3940(93)90925-B","volume":"160","author":"J Ruiz","year":"1993","unstructured":"Ruiz J, Martin I, Callado LF, Meana JJ, Barturen F, Garcia-Sevilla JA. Non-adrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer\u2019s disease. Neurosci Lett. 1993;160:109\u201312.","journal-title":"Neurosci Lett"},{"key":"1193_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.pharmthera.2017.03.009","volume":"178","author":"JX Li","year":"2017","unstructured":"Li JX. Imidazoline I2 receptors: an update. Pharmacol Ther. 2017;178:48\u201356.","journal-title":"Pharmacol Ther"},{"key":"1193_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0006-8993(03)02361-8","volume":"971","author":"RG Nagele","year":"2003","unstructured":"Nagele RG, D\u2019Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003;971:197\u2013209.","journal-title":"Brain Res"},{"key":"1193_CR37","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/glia.20967","volume":"58","author":"M Olabarria","year":"2010","unstructured":"Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer\u2019s disease. Glia. 2010;58:831\u20138.","journal-title":"Glia"},{"key":"1193_CR38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nbd.2004.12.013","volume":"18","author":"JA White","year":"2005","unstructured":"White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ. Differential effects of oligomeric and fibrillar amyloid-beta 1\u201342 on astrocyte-mediated inflammation. Neurobiol Dis. 2005;18:459\u201365.","journal-title":"Neurobiol Dis"},{"key":"1193_CR39","doi-asserted-by":"crossref","unstructured":"B\u00e9langer M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. 2011;14:724\u201338.","DOI":"10.1016\/j.cmet.2011.08.016"},{"key":"1193_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nn.4492","volume":"20","author":"ER Zimmer","year":"2017","unstructured":"Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim HI, et al. [(18)F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017;20:393\u20135.","journal-title":"Nat Neurosci"},{"key":"1193_CR41","doi-asserted-by":"crossref","unstructured":"Soucek T, Cumming R, Dargusch R, Maher P, Schubert D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron. 2003;39:43\u201356.","DOI":"10.1016\/S0896-6273(03)00367-2"},{"key":"1193_CR42","doi-asserted-by":"crossref","unstructured":"Smale G, Nichols NR, Brady DR, Finch CE, Horton WE. Evidence for apoptotic cell death in Alzheimer\u2019s disease. Exp Neurol. 1995;133:225\u201330.","DOI":"10.1006\/exnr.1995.1025"},{"key":"1193_CR43","doi-asserted-by":"crossref","unstructured":"Garaschuk O, Verkhratsky A. GABAergic astrocytes in Alzheimer\u2019s disease. 2019;11:1602\u20134.","DOI":"10.18632\/aging.101870"},{"key":"1193_CR44","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr.","year":"2016","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539\u201347.","journal-title":"Neurology"},{"key":"1193_CR45","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","volume":"19","author":"G Chetelat","year":"2020","unstructured":"Chetelat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias. Lancet Neurol. 2020;19:951\u201362.","journal-title":"Lancet Neurol"},{"key":"1193_CR46","doi-asserted-by":"publisher","first-page":"17513","DOI":"10.1073\/pnas.0602841103","volume":"103","author":"U Wilhelmsson","year":"2006","unstructured":"Wilhelmsson U, Bushong EA, Price DL, Smarr BL, Phung V, Terada M, et al. Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury. Proc Natl Acad Sci USA. 2006;103:17513\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1193_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ceb.2015.02.004","volume":"32","author":"EM Hol","year":"2015","unstructured":"Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015;32:121\u201330.","journal-title":"Curr Opin Cell Biol"},{"key":"1193_CR48","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1093\/nar\/gkq1182","volume":"39","author":"A Stahlberg","year":"2011","unstructured":"Stahlberg A, Andersson D, Aurelius J, Faiz M, Pekna M, Kubista M, et al. Defining cell populations with single-cell gene expression profiling: correlations and identification of astrocyte subpopulations. Nucleic Acids Res. 2011;39:e24.","journal-title":"Nucleic Acids Res"},{"key":"1193_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00401-009-0619-8","volume":"119","author":"MV Sofroniew","year":"2010","unstructured":"Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119:7\u201335.","journal-title":"Acta Neuropathol"},{"key":"1193_CR50","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.tins.2009.08.002","volume":"32","author":"MV Sofroniew","year":"2009","unstructured":"Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009;32:638\u201347.","journal-title":"Trends Neurosci"},{"key":"1193_CR51","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jnc.13399","volume":"136","author":"A Ishiki","year":"2016","unstructured":"Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, et al. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer\u2019s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem. 2016;136:258\u201361.","journal-title":"J Neurochem"},{"key":"1193_CR52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0165-5728(94)00180-V","volume":"57","author":"P Mecocci","year":"1995","unstructured":"Mecocci P, Parnetti L, Romano G, Scarelli A, Chionne F, Cecchetti R, et al. Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer\u2019s disease and vascular dementia. J Neuroimmunol. 1995;57:165\u201370.","journal-title":"J Neuroimmunol"},{"key":"1193_CR53","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0197-4580(02)00090-8","volume":"24","author":"AK Vehmas","year":"2003","unstructured":"Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer\u2019s disease. Neurobiol Aging. 2003;24:321\u201331.","journal-title":"Neurobiol Aging"},{"key":"1193_CR54","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/glia.22295","volume":"60","author":"W Kamphuis","year":"2012","unstructured":"Kamphuis W, Orre M, Kooijman L, Dahmen M, Hol EM. Differential cell proliferation in the cortex of the APPswePS1dE9 Alzheimer\u2019s disease mouse model. Glia. 2012;60:615\u201329.","journal-title":"Glia"},{"key":"1193_CR55","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.neurobiolaging.2013.09.035","volume":"35","author":"W Kamphuis","year":"2014","unstructured":"Kamphuis W, Middeldorp J, Kooijman L, Sluijs JA, Kooi EJ, Moeton M, et al. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer\u2019s disease. Neurobiol Aging. 2014;35:492\u2013510.","journal-title":"Neurobiol Aging"},{"key":"1193_CR56","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.4049\/jimmunol.0903382","volume":"184","author":"P Chakrabarty","year":"2010","unstructured":"Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, et al. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol. 2010;184:5333\u201343.","journal-title":"J Immunol"},{"key":"1193_CR57","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.nbd.2008.08.001","volume":"32","author":"P Edison","year":"2008","unstructured":"Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, et al. Microglia, amyloid, and cognition in Alzheimer\u2019s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008;32:412\u20139.","journal-title":"Neurobiol Dis"},{"key":"1193_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/srep16404","volume":"5","author":"M Scholl","year":"2015","unstructured":"Scholl M, Carter SF, Westman E, Rodriguez-Vieitez E, Almkvist O, Thordardottir S, et al. Early astrocytosis in autosomal dominant Alzheimer\u2019s disease measured in vivo by multi-tracer positron emission tomography. Sci Rep. 2015;5:16404.","journal-title":"Sci Rep"},{"key":"1193_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2967\/jnumed.110.087031","volume":"53","author":"SF Carter","year":"2012","unstructured":"Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, et al. Evidence for astrocytosis in prodromal alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53:37\u201346.","journal-title":"J Nucl Med"},{"key":"1193_CR60","doi-asserted-by":"crossref","unstructured":"Frost GR, Li YM. The role of astrocytes in amyloid production and Alzheimer\u2019s disease. Open Biol. 2017;7:170228.","DOI":"10.1098\/rsob.170228"},{"key":"1193_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/srep42991","volume":"7","author":"AL Hallmann","year":"2017","unstructured":"Hallmann AL, Arauzo-Bravo MJ, Mavrommatis L, Ehrlich M, Ropke A, Brockhaus J, et al. Astrocyte pathology in a human neural stem cell model of frontotemporal dementia caused by mutant TAU protein. Sci Rep. 2017;7:42991.","journal-title":"Sci Rep"},{"key":"1193_CR62","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/bpa.12538","volume":"27","author":"I Ferrer","year":"2017","unstructured":"Ferrer I. Diversity of astroglial responses across human neurodegenerative disorders and brain aging. Brain Pathol. 2017;27:645\u201374.","journal-title":"Brain Pathol"},{"key":"1193_CR63","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1093\/brain\/awz260","volume":"142","author":"H Wilson","year":"2019","unstructured":"Wilson H, Dervenoulas G, Pagano G, Tyacke RJ, Polychronis S, Myers J, et al. Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson\u2019s disease: an in vivo11C-BU99008 PET study. Brain. 2019;142:3116\u201328.","journal-title":"Brain"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01193-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01193-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01193-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T01:28:55Z","timestamp":1725413335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01193-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1193"],"URL":"https:\/\/doi.org\/10.1038\/s41380-021-01193-z","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]},"assertion":[{"value":"26 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PE is a consultant to Roche, Pfizer and Novo Nordisk. He has received speaker fees from Novo Nordisk, Pfizer, Nordea, Piramal Life Science. He has received educational and research grants from GE Healthcare, Novo Nordisk, Piramal Life Science\/Life Molecular Imaging, Avid Radiopharmaceuticals and Eli Lilly. He is an external consultant to Novo Nordisk and a member of their Scientific Advisory Board. PMM acknowledges consultancy fees from Roche, Adelphi Communications, Celgene and Biogen. He has received honoraria or speakers\u2019 honoraria from Novartis, Biogen and Roche and has received research or educational funds from Biogen, Novartis, GlaxoSmithKline and Nodthera.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}